|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Dyslipidemia - Shift from statins to add-ons
Datamonitor, Nov 2003, Pages: 294
Introduction
In the absence of pipeline compounds that can exceed the efficacy of statins, a number of trends have been identified. Pipeline developments are focusing on therapies that target lipid parameters inadequately controlled with statins, adjunctive therapies with novel mechanisms of action and statin/non-statin anti-dyslipidemic and statin/non anti-dyslipidemic single pill combinations
Scope
- Determination of the size of the hypercholesterolemia population in the seven major markets and summarization of the prevalence of low HDL cholesterol
- Quantitative overview of product development by class and phase to assess competitor activity and licensing opportunities
- In-depth analysis of clinical and market factors for late-stage statin and non-statin developmental therapies, including sales forecasts to 2011
- Overview of innovative early stage therapies, identifying promising development strategies and programs
Report Highlights
Although statins will continue to dominate the market, these drugs have been plagued by safety concerns, which have delayed the approval of both Crestor and Livalo.
The dyslipidemia R&D pipeline consists of 15 novel classes and increased availability of adjunctive therapies will lead to vast improvements in the treatment of more ‘difficult-to-treat’ patients.
Following greater acceptance of combination therapy, current developments are focusing on multi-modal therapies and statin single pill combinations.
Reasons to Purchase
- Recognize key areas within the current treatment of dyslipidemia that are inadequately served
- Gain an independent view of the R&D activity in the market
- Determine the gaps in the market, in order to position developmental products, and identify lucrative licensing and co-marketing opportunities
Customers who bought this item also bought
Stakeholder Insight: Dyslipidemia - Titration versus Combination Therapy
Drugs of Tomorrow 2001: Dyslipidemia - The Advent of Third Generation and Combination Statins
Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
Commercial Perspectives: Anti-dyslipidemics - A tale of two launches
Market Dynamics: Anti-dyslipidemics - Third Generation Statins Superfluous to Market Requirements?
Chinese Markets for Polybutadiene Rubber (BR)
Market Dynamics 2001: Anti-Dyslipidemics - Life Beyond Lipid Lowering
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Drugs of Tomorrow 2001: Stable Angina - An Unsatisfactory R&D Pipeline Facing Chronic Unmet Needs
|
|
|
|
